Incyte’s Jakafi Flunks In Phase III Myelofibrosis Study As Loss Of Exclusivity Nears

The company said it would discontinue the Phase III LIMBER-304 trial in patients who had inadequate response to Jakafi when an analysis indicated the study would not reach its primary endpoint.